Aurora Cannabis Inc. (ACB:CA) Q2 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed bag: strong growth in medical cannabis and plant propagation segments, but declining consumer cannabis revenue and increased SG&A expenses. The Q&A highlights structural advantages in international markets but reveals uncertainties in regulatory environments and cash flow challenges. Despite positive adjusted net income and margin improvements, negative free cash flow and unclear guidance on regulatory impacts temper optimism. Without market cap details, a neutral stance is prudent, reflecting balanced positive and negative factors.
Key Financial Performance
Net Revenue $90 million, an 11% increase year-over-year. This growth was driven by record global medical cannabis revenue (15% increase) and record international revenue (22% increase).
Consolidated Adjusted Gross Margin 61%, a 700 basis points improvement year-over-year. This was due to higher cannabis margins from increased international revenue.
Adjusted EBITDA $15 million, a 52% increase year-over-year. This growth exceeded top-line growth by a factor of 5, driven by substantial increases in gross profit.
Medical Cannabis Net Revenue $70.5 million, a 15% increase year-over-year. This was due to 22% growth in international markets and strong contributions from Canadian medical cannabis.
Medical Cannabis Adjusted Gross Margin 69%, up from 68% year-over-year. This increase was driven by higher revenue in international markets, which have higher margins.
Consumer Cannabis Net Revenue $6.9 million, down from $10.4 million year-over-year. This decline was due to a strategic decision to prioritize higher-margin medical cannabis sales.
Consumer Cannabis Adjusted Gross Margin 27%, up from 15% year-over-year. This increase was due to sales of higher-margin products and cost improvements.
Plant Propagation Net Revenue $11.6 million, a 34% increase year-over-year. This growth was driven by higher orchid sales.
Plant Propagation Adjusted Gross Margin 10%, down from 19% year-over-year. This decline was due to inventory write-offs caused by a nonrecurring quality issue and surplus crops not sold in the first quarter.
Adjusted SG&A $35.5 million, a 12% increase year-over-year. This was due to higher freight and logistics costs and investments in commercial teams in Europe and Australia.
Adjusted Net Income $7.1 million, up from $3 million year-over-year. This improvement was due to an increase in adjusted gross profit, partially offset by higher adjusted SG&A.
Free Cash Flow Negative $42.3 million, compared to negative $26.4 million year-over-year. This reflects expected cash outflows typical for the second quarter of the fiscal year.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Proprietary cultivars: Launched two proprietary cultivars in Poland, noted as the highest potency medical cannabis products in the country.
Vape products: Successfully launched proprietary cultivar-specific inhalable cannabis extracts in the U.K., performing well in the market.
Global medical cannabis: Net revenue rose 15% to $70.5 million, with international revenue growing 22%.
Germany: Increased revenue during the quarter, gaining share based on strong reputation among wholesalers, distributors, and pharmacists. Imports have grown significantly, and regulatory changes are being monitored.
Poland: Market size doubled from 2023 to 2025, with robust revenue growth driven by new product launches and regulatory expertise.
Australia: Second largest market outside Canada, representing a $1 billion opportunity with rapid expansion over the past two years.
U.K.: Expanding distribution and clinic relationships, leveraging lighter competition in premium segments.
Other European markets: Positive developments in Spain, France, Switzerland, Austria, Turkey, and Ukraine, with increasing regulatory alignment and market integration.
Operational efficiencies: Doubling production at the German manufacturing site to align with Canadian sites, targeting yield and operational efficiencies.
Vertical integration: Lower production costs achieved through focus on yield, potency improvement, and operational efficiencies.
Global leadership: Positioned as a leader in global medical cannabis with a focus on profitable growth and regulatory expertise.
Regulatory alignment: Advantage in international markets due to compliance with stringent EU GMP standards and regulatory engagement.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Changes in Germany: Potential modifications to the telehealth framework and home delivery regulations in Germany could pose challenges, particularly for patients in rural areas, impacting accessibility and potentially reducing market share.
Supply Chain and Production Costs: Higher freight and logistics costs, especially from increasing sales to Europe, and investments in commercial teams in Europe and Australia have increased operational expenses.
Consumer Cannabis Revenue Decline: Net revenue from consumer cannabis decreased from $10.4 million to $6.9 million, reflecting a strategic shift but also a potential risk of losing market presence in this segment.
Plant Propagation Quality Issues: Nonrecurring quality issues and surplus crops not sold led to inventory write-offs, reducing margins in the plant propagation segment.
Free Cash Flow Deficit: Free cash flow was negative $42.3 million, reflecting expected cash outflows but still a financial challenge to address.
Regulatory Barriers in Emerging Markets: Lengthy registration processes and stringent regulatory standards in markets like Poland and Spain could slow market entry and expansion.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: Consolidated net revenue is expected to increase year-over-year, driven primarily by 8% to 12% growth in the global medical cannabis segment.
Plant Propagation Revenue: Plant propagation revenue is expected to perform in line with traditional seasonal trends, with 25% to 35% of revenues normally earned in the second half of the calendar year.
Adjusted Gross Margins: Consolidated adjusted gross margins are expected to remain strong, driven primarily by industry-leading margins in the cannabis business. Plant propagation adjusted gross margins are expected to mostly perform in line with historical trends.
Adjusted EBITDA Growth: Continued strength in adjusted gross margins and higher global medical cannabis revenue should lead to year-over-year annual adjusted EBITDA growth.
Free Cash Flow: Free cash flow is expected to be positive in Q3 2026 due to continued strong performance and improved operating cash yield.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the realistic goal for medical gross margins, and why are the margins structurally better than expected?
A:The realistic goal for medical gross margins is influenced by multiple factors. Margins are structurally better due to reduced production costs, improved yield and genetics, higher margins in markets outside North America, and efficiencies in execution. These include using common medicinal cultivars globally and achieving production efficiencies in markets like Poland, Germany, and the U.K.
Q:Are there advantages in Germany due to competitors facing difficulties with product certification?
A:Yes, Germany is a challenging market for product certification under EU GMP standards. Aurora's Canadian and German facilities are certified and vertically integrated, ensuring consistent, high-quality supply. This creates an advantage over competitors facing certification issues.
Q:Why was there a significant drop in accounts payable in Q2 compared to Q1?
A:The drop in accounts payable in Q2 is due to historical trends where cash outflows typically occur in the second quarter due to various activities.
Q:What is the impact of the proposed changes to the budget in Canada regarding the price ceiling for medical cannabis veterans?
A:The proposed changes could disrupt the support system for veteran patients, affecting safe and consistent access to cannabis medications. Aurora is evaluating the impact and next steps, but it is too early to comment definitively.
Q:Did the halt in cannabis import permits in Germany impact Aurora, and what is the status of price compression in the German market?
A:The halt in cannabis import permits in Germany did not disrupt Aurora due to its strong relationship with regulators and permit staging. Price compression is mostly seen in the value segment, while core and premium product pricing remains stable.
Q:What led to the decision to double production at the Leuna production facility in Germany?
A:The decision was based on the success of the facility, which mirrors practices and genetics from Canada. Upgrades to lighting and irrigation systems and the facility's role as a showcase for stakeholders contributed to the decision.
Q:Why were sales in Australia softer in the quarter?
A:Sales in Australia were softer due to the market's focus on value products, which face increased competition. Aurora is transitioning to core and premium products, which will take time but is expected to improve performance.
Q:Is downstream integration necessary in the U.K. and Poland, and what are the regulatory constraints?
A:In Poland, Aurora cannot be a wholesaler or distributor but partners with clinics. In the U.K., clinics are important, and Aurora partners with wholesalers and clinics. Aurora remains flexible and evaluates opportunities for vertical integration.
Q:What are the timelines for potential regulatory changes in Germany and Australia?
A:In Germany, the proposal from the Health Minister will see more clarity by the end of November, with debates extending into spring. In Australia, timelines are open-ended, with regulatory agencies reviewing various aspects, including product testing.
Q:Review of Unclear Management Responses
A:Management avoided giving a direct answer regarding the impact of the proposed changes to the budget in Canada for medical cannabis veterans, citing the newness of the announcement and uncertainty in timelines. Similarly, timelines for regulatory changes in Australia were described as open-ended without specific details.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Canada cannabis
Consolidated
GMP facility
Germany market
Leuna
North America
advantage
cannabis company
cannabis market
clinic
country cannabis
development
discussion
engagement
experience
flow cash
improvement efficiency
improvement increase
investment
leader cannabis
marketplace
modification
momentum
others
outlook
physician
potency
premium product
priority
product consistency
product market
production
propagation line
quality premium
reason
regulator
site
strength cannabis
telehealth framework
veteran
ACB Transcript
Aurora Cannabis Inc. (ACB:CA) Q4 2026 Earnings Call Transcript
Neutral6-11
Aurora Cannabis Inc. (ACB:CA) Q3 2026 Earnings Call Transcript
Unknown2-4
The earnings call summary suggests a mix of positive and neutral aspects. Positive factors include strong financial performance and strategic focus on profitable segments like global medical cannabis. However, uncertainties such as the exit from plant propagation, lack of specific timelines, and unclear management responses regarding revenue deceleration create a balanced outlook. The Q&A section did not reveal significant risks but highlighted strategic shifts and market exploration. Overall, the sentiment appears neutral due to the balanced nature of positive growth strategies and uncertainties in execution and market conditions.
Aurora Cannabis Inc. (ACB:CA) Q2 2026 Earnings Call Transcript
Unknown11-5
The earnings call presents a mixed bag: strong growth in medical cannabis and plant propagation segments, but declining consumer cannabis revenue and increased SG&A expenses. The Q&A highlights structural advantages in international markets but reveals uncertainties in regulatory environments and cash flow challenges. Despite positive adjusted net income and margin improvements, negative free cash flow and unclear guidance on regulatory impacts temper optimism. Without market cap details, a neutral stance is prudent, reflecting balanced positive and negative factors.
Aurora Cannabis Inc. (ACB) Q1 2026 Earnings Call Transcript
Positive8-6
The earnings call reveals a strong financial performance with record medical cannabis revenue and improved margins. Despite lower consumer cannabis revenue, strategic focus on high-margin medical cannabis and international growth are promising. Positive cash flow and no cannabis business debt highlight financial health. The Q&A section reveals challenges in Europe but also demonstrates management's proactive strategies. While SG&A expenses are higher, they are partly one-time. Overall, the optimistic guidance for future EBITDA and market expansion suggests a positive sentiment, likely resulting in a stock price increase in the short term.
ACB Slides
ACB Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
